scispace - formally typeset
B

Bharath Kumar Cheripelli

Researcher at University of Glasgow

Publications -  17
Citations -  1782

Bharath Kumar Cheripelli is an academic researcher from University of Glasgow. The author has contributed to research in topics: Stroke & Tenecteplase. The author has an hindex of 13, co-authored 16 publications receiving 1160 citations. Previous affiliations of Bharath Kumar Cheripelli include University of Melbourne & University of Hamburg.

Papers
More filters
Journal ArticleDOI

Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study

TL;DR: Evaluation of tenecteplase in larger trials of patients with acute stroke seems warranted, and to use imaging biomarkers to inform the design of a definitive phase 3 clinical trial.
Journal ArticleDOI

Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial

Martin Dennis, +1271 more
- 19 Jan 2019 - 
TL;DR: Although the treatment reduced the occurrence of depression, it increased the frequency of bone fractures and these results do not support the routine use of fluoxetine either for the prevention of post-stroke depression or to promote recovery of function.
Journal ArticleDOI

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Rustam Al-Shahi Salman, +933 more
- 29 Jun 2019 - 
TL;DR: The results exclude all but a very modest increase in the risk of recurrent intracranial haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haem orrhage.
Journal ArticleDOI

Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data

Götz Thomalla, +775 more
- 14 Nov 2020 - 
TL;DR: In patients who have had a stroke with unknown time of onset with a DWI-FLAIR or perfusion mismatch, intravenous alteplase resulted in better functional outcome at 90 days than placebo or standard care despite an increased risk of symptomatic intracranial haemorrhage.